Moderna Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
26.6%projected annual EPS growth
Analyst Coverage
19analysts covering
FY EPS (est.)
-$8.58next fiscal year
Monitoring Framework
Key Performance Indicators
Total Revenue Quarterly389MTarget: Up to 10% revenue growth in 2026
GAAP Operating Expenses Annually
Cash, Cash Equivalents, and Investments Quarterly7.5B
Watch Items
- FDA PDUFA Action Date for Seasonal Influenza Vaccine (mRNA-1010)Trigger: August 5, 2026Action: Monitor FDA decision and subsequent commercial launch preparations in the U.S.
- Pivotal Clinical Data Readouts for Intismeran (mRNA-4157) and Propionic Acidemia (mRNA-3927)Trigger: Pivotal data readouts expected in 2026Action: Evaluate clinical efficacy and safety profiles to support potential oncology and rare disease product launches
Research as of 2 Sep 2026